3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
6
Withdrawn
1
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lymphatic Diseases
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immune System Diseases
1
Carcinoma, Adenoid Cystic
1
AIDS-Related Complex
1
Interventions
Docetaxel
11
Prednisone
10
Leuprolide
10
Magnetic Resonance Spectroscopy
9
bicalutamide
8
Radiotherapy
7
Abiraterone Acetate
7
Biopsy
6
gallium 68 PSMA-11
5
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
5
Surveys and Questionnaires
5
Metformin
5
Goserelin
5
radium Ra 223 dichloride
4
enzalutamide
4
apalutamide
4
Specimen Handling
4
Injections
4
Androgen Antagonists
4
pembrolizumab
3
orteronel
3
cabazitaxel
3
abiraterone
3
Radiotherapy, Intensity-Modulated
3
Radiosurgery
3
Pioglitazone
3
Paclitaxel
3
Exercise
3
Brachytherapy
3
Blood Specimen Collection
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Prostatic Neoplasms
×
Lutetium-177
×
Clear all
NCT06881823
2025-12-29
NeoPSMA
Novartis
Phase 1/2
Withdrawn